What side effects are associated with this type of intervention?

Common treatments for bronchiectasis include antibiotics, bronchodilators, and airway clearance techniques. Antibiotics can cause side effects such as gastrointestinal upset, allergic reactions, and antibiotic resistance. Bronchodilators may lead to side effects like tremors, palpitations, and dry mouth. Airway clearance techniques, while generally safe, can sometimes cause discomfort, fatigue, or hemoptysis (coughing up blood). Non-invasive diagnostic tests, such as lung ultrasound or imaging, are generally safe but may occasionally cause minor discomfort or anxiety.

What prior FDA approvals exist?

The FDA has approved several treatments for Bronchiectasis, primarily focusing on managing symptoms and infections. Inhaled antibiotics like tobramycin and aztreonam lysine are commonly used to treat chronic Pseudomonas aeruginosa infections in Bronchiectasis patients. These treatments aim to reduce bacterial load and improve lung function. While the context does not provide specific information on non-invasive diagnostic tests for Bronchiectasis, such as biomarker detection or imaging, these methods are generally used to monitor disease progression and response to therapy.

What other types of research exist?

Promising novel alternatives for non-invasive diagnostic tests for bronchiectasis patients in 2024 include advanced imaging techniques like high-resolution computed tomography (HRCT) and lung ultrasound artefact analysis. Additionally, molecular profiling and the use of biomarkers such as N-terminal pro-brain natriuretic peptide (NT-proBNP) are being explored for their potential to provide early and accurate diagnosis.

← Back to Search

Diagnostic Test

Lung Ultrasound for Lung Transplant

N/A

Recruiting

Led By Tathagat Narula, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 0 to month 12

Awards & highlights

No Placebo-Only Group

Summary

This trial is looking for a safer and cheaper way to check for lung problems in lung transplant patients without using risky procedures.

Who is the study for?

This trial is for adults over 18 who have had a lung or heart-lung transplant. They must be symptom-free, with clear chest X-rays and normal breathing test results (FEV1) that haven't dropped more than 10% from their usual. People can't join if they can't consent or have conditions like subcutaneous emphysema that make it hard to get good ultrasound images.

What is being tested?

The study is testing the use of lung ultrasounds as a non-invasive method to detect lung rejection and infection in patients who've received lung transplants. It aims to find safer ways to diagnose these serious complications without invasive procedures.

What are the potential side effects?

Since the intervention involves only lung ultrasound, which is non-invasive, there are typically no side effects associated with this procedure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 0 to month 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 0 to month 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 0 to month 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Establish predictive value of lung ultrasound

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Receiving UltrasoundExperimental Treatment1 Intervention

Every patient will receive a lung ultrasound prior to each scheduled bronchoscopy until the study stops.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Lung ultrasound

2021

N/A

~2160

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Bronchiectasis include antibiotics, mucoactive agents, and airway clearance techniques. Antibiotics target bacterial infections that exacerbate symptoms, reducing inflammation and preventing further lung damage. Mucoactive agents, such as hypertonic saline, help to thin and loosen mucus, making it easier to clear from the airways. Airway clearance techniques, including chest physiotherapy and exercise, facilitate the removal of mucus, improving lung function and reducing the risk of infections. These treatments are crucial for Bronchiectasis patients as they help manage symptoms, prevent exacerbations, and improve overall quality of life.

Self-management for bronchiectasis.Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.